Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY E GERSHENWALD and JONATHAN L CURRY.
Connection Strength
1.632
-
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.
Score: 0.657
-
Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol. 2014; 1102:679-95.
Score: 0.470
-
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
Score: 0.129
-
Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
Score: 0.117
-
Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. Arch Pathol Lab Med. 2021 12 01; 145(12):1505-1515.
Score: 0.051
-
Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.
Score: 0.044
-
Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
Score: 0.043
-
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
Score: 0.036
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.031
-
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.
Score: 0.029
-
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15; 118(16):4014-23.
Score: 0.025